[en] BACKGROUND: The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months. METHODS: The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed. RESULTS: A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8% in the tacrolimus group and 60.6% in the CsA-ME group, graft survival rates were 88.0% and 86.9% and patient survival rates were 96.6% and 96.7%, respectively. The estimated combined endpoint-free survival rate was 71.4% with tacrolimus and 55.4% with CsA-ME (P <or= 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2% versus 2.6%, P <or= 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 +/- 90.9 micromol/L with tacrolimus and 149.0 +/- 92.1 micromol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3% versus 12.6%, P <or= 0.0003, chi-square test). CONCLUSIONS: Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.
Disciplines :
Urology & nephrology Surgery
Author, co-author :
Krämer, Bernhard K.; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Del Castillo, Domingo; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Gonwa T, Johnson C, Ahsan N et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048-2053
Meier-Kriesche HU, Kaplan B. Ciclosporin microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with Sandimmune. Am J Transplant 2002; 2: 100-104
Mayer AD for the European Tacrolimus Multicentre Renal Study Group. Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34: 1491-1492
Jurewicz WA. Tacrolimus versus ciclosporin immunnosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 (Suppl 1): 7-11
Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and ciclosporin in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782
Radermacher J, Meiners M, Bramlage C et al. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. Transpl Int 1998; 11: 3-10
Margreiter R for the European Tacrolimus versus Ciclosporin Microemusion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746
Montagnino G, Krämer BK, Arias M for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in kidney transplantation: twelve-month follow-up. Transplant Proc 2002; 34: 1635-1637
Krämer BK, Montagnino G, Del Castillo D et al. Efficacy and safety of tacrolimus compared with ciclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005, 20: 968-973
Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422
Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
Chi GYH. Some issues with composite endpoints in clinical trials. Fundamental Clin Pharmacol 2005; 19: 609-619
Krämer BK, Zülke C, Kammerl MC et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982-987
Johnson RWG, Kreis H, Oberbauer R et al. Sirolimus allows early ciclosporin withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786
Groth CG, Baeckman L, Morales JM et al. for the Sirolimus European Renal Transplant Study Group. Sirolimus (Rapamycin)-based therapy in human renal transplantation. Similar efficacy and different toxicity compared with ciclosporin. Transplantation 1999; 67: 1036-1042
Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Br Med J 2005; 331: 810-820
Wissing KM, Abramowicz D, Broeders N et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70: 464-472
Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation 2003; 75: SS3-SS24
